https://scholars.lib.ntu.edu.tw/handle/123456789/641592
標題: | Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study | 作者: | Yau, Thomas Kaseb, Ahmed ANN-LII CHENG Qin, Shukui Zhu, Andrew X Chan, Stephen L Melkadze, Tamar Sukeepaisarnjaroen, Wattana Breder, Valery Verset, Gontran Gane, Edward Borbath, Ivan Rangel, Jose David Gomez Ryoo, Baek-Yeol Makharadze, Tamta Merle, Philippe Benzaghou, Fawzi Milwee, Steven Wang, Zhong Curran, Dominic Kelley, Robin Kate Rimassa, Lorenza |
公開日期: | 四月-2024 | 卷: | 9 | 期: | 4 | 來源出版物: | The lancet. Gastroenterology & hepatology | 摘要: | The aim of the COSMIC-312 trial was to evaluate cabozantinib plus atezolizumab versus sorafenib in patients with previously untreated advanced hepatocellular carcinoma. In the initial analysis, cabozantinib plus atezolizumab significantly prolonged progression-free survival versus sorafenib. Here, we report the pre-planned final overall survival analysis and updated safety and efficacy results following longer follow-up. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/641592 | ISSN: | 24681253 | DOI: | 10.1016/S2468-1253(23)00454-5 |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。